Travere Therapeutics Plans to Offer $400M Convertible Senior Notes
Travere Therapeutics announced its intention to offer, subject to market and other conditions, $400M aggregate principal amount of convertible senior notes due 2032 in an underwritten offering. Travere intends to use a portion of the net proceeds from the offering to repurchase a portion of its currently outstanding convertible notes. J.P. Morgan, Jefferies, and Leerink Partners are acting as joint book-running managers for the offering.
